Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Synbias Pharma is a specialty pharmaceutical company dedicated to the development and large-scale production of high-potency Active Pharmaceutical Ingredients (APIs), specifically focusing on anthracycline-based oncology medications. The company is recognized for its expertise in complex chemical synthesis and the manufacturing of critical chemotherapy agents such as doxorubicin, epirubicin, and idarubicin. Operating under strict Good Manufacturing Practice (GMP) standards, Synbias provides high-quality generic substances to pharmaceutical manufacturers and healthcare providers worldwide. Headquartered in Switzerland with historical manufacturing roots in Ukraine, the company supports the treatment of various malignancies including breast cancer, leukemia, and lymphoma. Their business model encompasses both the supply of off-the-shelf APIs and custom synthesis services for global partners.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Synbias Pharma.